




REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

www.elsevier.es/rgmx



ORIGINAL ARTICLE

Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico[☆]



O. Novoa-Farias^a, A.C. Frati-Munari^{b,*}, M.A. Peredo^c, S. Flores-Juárez^c,
O. Novoa-García^a, J. Galicia-Tapia^a, C.E. Romero-Carpio^a

^a División de Microbiología Clínica, Unidad de Diagnóstico Microbiológico UDMSC, Mexico City, Mexico

^b Departamento de Medicina Interna, Hospital Médica Sur, Mexico City, Mexico

^c Alliance for the prudent use of antibiotics (APUA), Chapter México, Mexico City, Mexico

Received 27 June 2016; accepted 25 October 2016

Available online 18 April 2017

KEYWORDS

Rifaximin;
Bacterial resistance;
Bacterial
susceptibility;
Southeast Mexico;
Gastroenteritis;
Acute diarrhea

Abstract

Introduction: Enteropathogenic bacteria isolated in Mexico City have shown a high rate of resistance to different antibiotics, with the exception of rifaximin (RIF). RIF is a nonabsorbable antibiotic that reaches high fecal concentrations ($\approx 8,000 \mu\text{g/g}$). Susceptibility to antimicrobials can vary in different geographic regions.

Aim: To study the susceptibility to rifaximin and other antimicrobials of enteropathogenic bacteria isolated in patients with acute diarrhea in the southeastern region of Mexico.

Material and methods: A total of 614 strains of bacteria isolated from patients with acute diarrhea from 4 cities in Southeast Mexico were analyzed. An antibiogram with the following antibiotics was created: ampicillin (AMP), trimethoprim/sulfamethoxazole (T-S), neomycin (NEO), furazolidone (FUR), ciprofloxacin (CIP), chloramphenicol (CHL), and fosfomicin (FOS), assessed through the agar diffusion method at the standard concentrations recommended by the Clinical and Laboratory Standards Institute (CLSI) and the American Society for Microbiology (ASM), and RIF, assessed through microdilution at 4 concentrations.

Results: The bacteria were *Escherichia coli* (55%), as the majority, in all its pathogenic variants, *Shigella* (16.8%), *Salmonella* (15.3%), *Aeromonas* (7.8%), and less than 5% *Campylobacter*, *Yersinia*, *Vibrio*, and *Plesiomonas*. The accumulated overall susceptibility to RIF was 69.1, 90.8, 98.9, and 100% at concentrations of 100, 200, 400, and 800 $\mu\text{g/ml}$, respectively. Overall susceptibility to other antibiotics was FOS 82.8%, CHL 76.8%, CIP 73.9%, FUR 64%, T-S 58.7%,

[☆] Please cite this article as: Novoa-Farias O, Frati-Munari AC, Peredo MA, Flores-Juárez S, Novoa-García O, Galicia-Tapia J, et al. Susceptibilidad a la rifaximina y otros antimicrobianos de bacterias aisladas en pacientes con infecciones gastrointestinales agudas en el sureste de México. *Revista de Gastroenterología de México*. 2017;82:226–233.

* Corresponding author. Alfa Wasserman S.A. de C.V., Av. Insurgentes Sur 2453-803, Col. Tizapán San Ángel, Del. Álvaro Obregón, Mexico City, Mexico. Tel.: 54814707.

E-mail addresses: AFrati@alfawassermann.com, afratim@hotmail.com (A.C. Frati-Munari).

NEO 55.8%, and AMP 23.8%. Susceptibility to RIF at 400 and 800 μg was significantly greater than with the other antimicrobials ($P < .001$).

Conclusions: The data of the present study were similar to those of a previous study carried out in Mexico City: susceptibility to RIF in > 98% of the bacterial strains and a high frequency of resistance to several common antimicrobials.

© 2017 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Rifaximina;
Resistencia
bacteriana;
Susceptibilidad
bacteriana;
Sureste mexicano;
Gastroenteritis;
Diarrea aguda

Susceptibilidad a la rifaximina y otros antimicrobianos de bacterias aisladas en pacientes con infecciones gastrointestinales agudas en el sureste de México

Resumen

Antecedentes: Bacterias enteropatógenas aisladas en la Ciudad de México han mostrado una alta tasa de resistencia a diversos antibióticos, con excepción de la rifaximina (RIF). La RIF es un antibiótico no absorbible que alcanza altas concentraciones fecales ($\approx 8,000 \mu\text{g/g}$). La susceptibilidad a los antimicrobianos puede variar en distintas regiones geográficas.

Objetivo: Investigar la susceptibilidad a rifaximina y otros antimicrobianos de bacterias enteropatógenas aisladas de pacientes con diarrea aguda en el sureste de México.

Material y métodos: Se analizaron 614 cepas de bacterias aisladas de pacientes con diarrea aguda de 4 ciudades del sureste del México. Se realizó antibiograma con: ampicilina (AMP), trimetoprim/sulfametoxazol (T-S), neomicina (NEO), furazolidona (FUR), ciprofloxacino (CIP), cloranfenicol (CLO) y fosfomicina (FOS) por difusión en agar a las concentraciones estándar recomendadas por CLSI y ASM y RIF en 4 concentraciones por microdilución.

Resultados: La mayoría de las bacterias fueron *Escherichia coli* (55%) en todas sus variantes patógenas, *Shigella* (16.8%), *Salmonella* (15.3%), *Aeromonas* (7.8%) y menos de 5% *Campylobacter*, *Yersinia*, *Vibrio* y *Plesiomonas*. La susceptibilidad global acumulada a RIF fue del 69.1, el 90.8, el 98.9 y el 100% a las concentraciones de 100, 200, 400 y 800 $\mu\text{g/ml}$, respectivamente. La susceptibilidad global a los otros antibióticos fue: FOS 82.8%, CLO 76.8%, CIP 73.9%, FUR 64%, T-S 58.7%, NEO 55.8% y AMP 23.8%. La susceptibilidad a RIF 400 y 800 μg fue significativamente mayor que con los otros antimicrobianos ($p < 0.001$).

Conclusiones: Se encontraron datos similares a los de un estudio previo realizado en la Ciudad de México: susceptibilidad a RIF en > 98% de las cepas bacterianas y alta frecuencia de resistencia a varios antimicrobianos comunes.

© 2017 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Worldwide, 2 billion cases of acute diarrhea are calculated to occur yearly. This disease is the second cause of child mortality, preceded only by pneumonia. In recent decades, the extended use of oral rehydration solutions, together with improved sanitary conditions, have resulted in a noticeable drop in mortality from this type of diarrhea. Nevertheless, it continues to be one of the main causes of illness and death in children in the developing countries, with children under 5 years of age having a mean 3 diarrheic episodes per year.¹ Infections contribute to childhood malnutrition, given that each episode reduces the nutrients necessary for growth and development. In Mexico, there is evidence that up to 17.8% of children presenting with frequent episodes of diarrhea have clinical signs of malnutrition.²

There are numerous etiologies of diarrheic disease. The main origin in the developing countries is bacterial and parasitic infection, as a consequence of exposure to contaminated food and water. In Mexico, acute diarrhea

is the fifth cause of death in children between 1 and 4 years of age. Frequency is up to 16% greater in certain geographic zones, mainly in the Southeast (Chiapas, Tabasco, and Yucatán), as opposed to the Northern states of Mexico.^{3,4}

It is difficult to determine the etiology of this disease based solely on clinical symptoms, but in children under 5 years of age it is frequently due to viral infection, whereas in older children and adults the cause is often bacterial infection.⁵ Etiologic diagnosis enables treatment to be given that aids in reducing symptoms, shortens the illness, prevents complications, and reduces the spread of pathogens in the population. However, in the majority of cases antimicrobial therapy is empirical, making it necessary to conduct epidemiologic surveillance studies on causal organisms and antimicrobial susceptibility that take local or regional patterns into account. In a previous study,⁶ we reported on the antimicrobial susceptibility of the microorganisms causing acute diarrhea in 1,000 patients, children and adults, in Mexico City. That study revealed a high frequency of bacterial resistance to the common antimicrobials, whereas

rifaximin (RIF) demonstrated excellent antibacterial activity. It is a nonabsorbable, broad-spectrum antibiotic that reaches high concentrations in the intestinal lumen.⁷ One of the limitations of that study was that it only included a population in Mexico City. Given the high prevalence of diarrheic syndromes reported in other areas of the country, we decided to conduct a similar study on bacterial isolates from patients with acute diarrhea in 4 cities in the Southeast of Mexico.

Materials and methods

Bacterial isolates

A total of 614 bacterial strains were analyzed. They were isolated from feces from the same number of patients of both sexes and all ages that were clinically diagnosed with acute diarrhea. The samples came from 4 private laboratories in the cities of Veracruz, Veracruz (153 cases), Villahermosa, Tabasco (160 cases), Mérida, Yucatán (151 cases), and Tuxtla Gutiérrez, Chiapas (150 cases). The strains were conserved in milk broth and soy broth with glycerol and frozen at -70°C before their biochemical, serologic, and antimicrobial susceptibility identification. The following culture media were utilized in the initial sample isolations performed in each laboratory: MacConkey agar, MacConkey-sorbitol agar, Shigella-Salmonella agar, XLD agar, Campylobacter agar, Yersinia agar, TCBS agar, Brilliant Green agar, and tetrathionate broth.

The isolates were biochemically identified at each laboratory through manual and automatized systems: Autoscan 4, Walkaway/ (Micros Scan), or VITEK 2, with acceptance probability in their identification greater than 95%. Typing and serologic identification of certain bacterial species, such as *Escherichia coli* (*E. coli*), *Salmonella*, and *Shigella*

were done, using different commercial brands of specific antiserums and agglutination or conglutination reagents.

Antimicrobial susceptibility testing

Following the procedures established by the American Microbiology Society and the U.S. Clinical Laboratory Standards Institute (CLSI), the antimicrobial susceptibility testing was carried out using agar diffusion and dilution plating^{8,9} with the following antibiotic concentrations: ampicillin (AMP) 10 $\mu\text{g}/\text{ml}$, chloramphenicol (CHL) 30 $\mu\text{g}/\text{ml}$, ciprofloxacin (CIP) 50 $\mu\text{g}/\text{ml}$, fosfomicin (FOS) 50 $\mu\text{g}/\text{ml}$, furazolidone (FUR) 100 $\mu\text{g}/\text{ml}$, trimethoprim/sulfamethoxazole (T-S) 1.25/23.75 $\mu\text{g}/\text{ml}$, and neomycin (NEO) 30 $\mu\text{g}/\text{ml}$. RIF was tested at 4 different concentrations: 100, 200, 400, and 800 $\mu\text{g}/\text{ml}$. When strains were not susceptible to a given concentration, they were tested with successively higher ones. The minimum inhibitory concentration at which 90% of isolates are inhibited (MIC90) was considered for all the antibiotics, but MIC100 was considered for RIF.

Statistical analysis

Bacterial susceptibility to RIF was compared with that of the other antimicrobials through the Z-test. Statistical significance was set at a $p < 0.05$. The same test was employed to compare the results of the present analysis with those of the previously published study conducted in Mexico City. The statistical analysis was carried out using Statistica 8.0 and Stata 11 software packages.

Results

A total of 614 bacterial isolates were analyzed that came from the stool cultures of 308 males (50.1%) and 306 females




Figure 1 Frequency of bacterial isolates in 614 patients with acute gastroenteritis in four cities in the Southeast of Mexico.

(49.9%), the majority of whom were adolescents and young adults (65.9%). A total of 0.9% were under 10 years of age and 3.7% were above 70 years of age. Ninety-one percent of the samples were from outpatients and 9% were from hospitalized patients.

Bacteria. More than half of the isolates were identified as some serotype of "diarrheogenic" *E. coli*, one third were species of the *Shigella* and *Salmonella* genera, followed by *Aeromonas*, *Campylobacter*, *Yersinia*, *Vibrio*, and *Plesiomonas*, in that order (Figure 1).

Three quarters of the *E. coli* (77%) corresponded to the enteropathogenic *E. coli* (EPEC) serotypes and very few were enterohemorrhagic *E. coli* (O:157). The majority of the *Shigella* were *dysenteriae* and *flexneri*, whereas *Salmonella paratyphi* was the most frequent species of that genus. Table 1 shows the number and proportion of the other genera, species, and serotypes.

Antimicrobial susceptibility. Overall, 69.1% of the bacteria were susceptible to RIF at a concentration of 100 µg/ml and 90.8% were susceptible at 200 µg/ml, and almost all at higher concentrations (Figure 2). The bacterial species that more frequently required higher concentrations of RIF were *E. coli* and *Salmonella* (Table 2).

Table 3 shows the susceptibility of the different bacteria to the antibiotics tested. The bacteria that were susceptible ≥ 75% of the time were: EPEC only to RIF and FOS; enterotoxigenic *E. coli* to RIF and CHL; enterohemorrhagic *E. coli* to RIF, CIP, and CHL; *Shigella* to RIF, CIP, and FOS; *Salmonella* to RIF, CIP, FOS, and very close to CHL; and *Aeromonas* to the majority, except AMP, FUR, and FOS. The following were susceptible to almost all the antimicrobials: *Yersinia*, except to NEO and AMP; *Campylobacter*, except to CIP and T-S; *Vibrio*, except to NEO and AMP; and *Plesiomonas*, except to AMP. AMP showed good activity only against *Campylobacter*.

Overall, the susceptibility of the 614 bacterial strains to the antibiotics tested (Figure 3) showed that more than




Figure 2 Overall susceptibility of the 614 bacteria at rifaximin concentrations of 100, 200, 400, and 800 µg/ml in accumulated form was 69.1, 90.8, 98.9, and 100%, respectively. The bacteria that were not susceptible to 100 µg/ml were tested at successively higher concentrations. The number of bacteria is shown at the top of the columns.

three quarters of the cases were resistant to AMP and almost half were resistant to T-S and NEO. Resistance to FUR occurred in 36% and to CIP in 26%, whereas the majority of the bacteria were susceptible to CHL (77%), FOS (88%), and RIF at 400 µg/ml (98.9%). The accumulated proportion of strains susceptible to RIF < 400 and < 800 was significantly greater than to the other antimicrobials ($p < 0.001$).

Discussion

Susceptibility means that the growth of a given bacterium is inhibited at the concentration of antibiotic that is reached at the infection site with the recommended dose; the concentrations are frequently the serum concentrations. The

Table 1 Bacteria and their serotypes isolated in 614 patients with acute gastroenteritis.

Bacteria	No.	Serotypes
Enteropathogenic <i>Escherichia coli</i> (EPEC) A, B, and C groups	261	0127:B8, 0111:B4, 055:B5, 026:B6, 0119:B4, 0128:B12:B17, 086:B7, 0126:B16, 0142:B86, 0119:B90, 0129:B17, 086:B7, 0126:B16
Enterotoxigenic <i>Escherichia coli</i> (ETEC)	67	Only thermolabile toxin producers
Enterohemorrhagic <i>Escherichia coli</i> (EHEC)	10	O:157
<i>Shigella dysenteriae</i>	63	Serotypes agglutinable in specific antisera
<i>Shigella flexneri</i>	24	Serotypes agglutinable in specific antisera
<i>Shigella boydii</i>	10	Serotypes agglutinable in specific antisera
<i>Shigella sonnei</i>	2	Serotypes agglutinable in specific antisera
<i>Shigella spp.</i>	4	
<i>Salmonella</i> A group	43	<i>Salmonella paratyphi</i>
<i>Salmonella</i> B group	16	<i>Salmonella typhimurium</i>
<i>Salmonella</i> C1 group	7	<i>Salmonella choleraesuis</i>
<i>Salmonella</i> C2 group	12	<i>Salmonella newport</i>
<i>Salmonella enteritidis</i>	7	<i>Salmonella enteritidis</i>
<i>Yersinia enterocolitica</i>	11	
<i>Campylobacter jejuni</i>	11	
<i>Vibrio vulnificus</i>	5	
<i>Aeromonas spp.</i>	48	
<i>Plesiomonas shigelloides</i>	4	

Table 2 Bacterial susceptibility to different rifaximin concentrations.

Bacteria	No.	100 $\mu\text{g/ml}$	200 $\mu\text{g/ml}$	400 $\mu\text{g/ml}$	800 $\mu\text{g/ml}$
EPEC	261	48.7	26.4	23.7	1.1
ETEC	67	79.1	9.0	5.9	5.9
EHEC	10	80.0	20.0	-	-
<i>Shigella</i>	103	97.1	2.9	-	-
<i>Salmonella</i>	94	67.0	31.9	1.1	-
<i>Yersinia</i>	11	81.8	18.2	-	-
<i>Campylobacter</i>	11	81.8	18.2	-	-
<i>Vibrio</i>	5	100.0	-	-	-
<i>Plesiomonas</i>	4	100.0	-	-	-
<i>Aeromonas</i>	48	95.8	4.2	-	-
Total	614	69.1	18.9	10.9	1.1

Results expressed in % of the susceptible bacteria.

EHEC: Enterohemorrhagic *Escherichia coli*; EPEC: Enteropathogenic *Escherichia coli*; ETEC: Enterotoxigenic *Escherichia coli*.

Table 3 Susceptibility of the bacterial isolates to the antimicrobials tested.

Bacteria	RIF (400 $\mu\text{g/ml}$)	FOS	CHL	CIP	FUR	T-S	NEO	AMP
EPEC	98.9	89.6	72.6	57.6	67.3	55.3	47.6	31.3
ETEC	94.1	70	79	43	70	46	54	28
EHEC	100	60	80	100	60	20	60	40
<i>Shigella</i>	100	87.8	71.1	90.2	73.1	75.0	74.1	57.7
<i>Salmonella</i>	100	87	74.2	99.6	42	32	54.4	41.4
<i>Yersinia</i>	100	100	82	100	100	100	27	18
<i>Campylobacter</i>	100	100	100	55	100	100	0	0
<i>Vibrio</i>	100	100	100	100	100	100	0	0
<i>Plesiomonas</i>	100	100	100	75	75	75	75	50
<i>Aeromonas</i>	100	63	79	100	52	92	83	20
Total	98.9	82.8	76.8	73.9	64	58.7	55.8	23.8

Results expressed as % of susceptible bacteria.




Figure 3 Overall susceptibility of the bacteria to the antibiotics tested. The percentage of each antimicrobial is shown at the top of the columns. AMP: ampicillin; CHL: chloramphenicol; CIP: ciprofloxacin; FOS: fosfomycin; FUR: furazolidone; NEO: neomycin; RIF: rifaximin (concentration of 400 $\mu\text{g/ml}$); T-S; trimethoprim-sulfamethoxazole.

antimicrobial concentrations for deciding if a bacterium is susceptible or resistant have been defined and published,⁹ and are those that have been used in the present study, except for RIF. Its concentration for defining susceptibility has not been established, but other studies have used

cutoff points of 32, 128, and 256 $\mu\text{g/ml}$.¹⁰⁻¹² Because it is a nonabsorbable antibiotic, RIF reaches very high concentrations in the intestinal lumen. With its recommended dose for the treatment of acute gastrointestinal infections (800 mg daily for 3 days), fecal concentrations of RIF of up to a mean 8,000 $\mu\text{g/g}$ have been reported.¹³ Therefore, in the present study we used higher concentrations than those reported by other authors, up to 400 and 800 $\mu\text{g/ml}$. They have more clinical significance, even though they are 10 to 20 times lower than the mean concentrations found in stools.

Our present findings from the stool cultures analyzed in patients with symptoms of acute diarrhea from 4 cities in the Southeast of Mexico confirm the data from our previous study conducted in Mexico City with the same methodology on stool cultures from 1,000 patients presenting with acute gastroenteritis.⁶ The genera and species of the bacterial isolates were similar in the 2 studies, except for a greater proportion of *Shigella* in the present sample (16.1 vs 12.0% from the previous study), and this difference was statistically significant ($Z = 2.27$, $p < 0.05$). In both studies, a low frequency of gastrointestinal bacterial pathogens susceptible to AMP, NEO, T-S, and FUR, more frequent susceptibility to CIP and CHL, and high percentages of susceptibility to FOS and RIF were observed.

Antimicrobial treatment of bacterial infections is useful for reducing symptoms, shortening the illness, and decreasing the transmission of the bacterial pathogen, but the widespread use of antimicrobials favors the appearance of resistant strains and the transmission of resistance to other bacteria.¹⁴ The appearance of *E. coli* strains and other enterobacteria that produce extended-spectrum beta-lactamases has become a therapeutic problem that can be transmitted from one country to another.¹⁵ Moreover, in many cases antimicrobials are not indicated, such as in viral respiratory or gastrointestinal infections, or in cases of self-medication, the doses and treatment duration are insufficient. Ever-growing bacterial resistance is a health problem, especially in severe cases. An increase in bacterial resistance in many infections, including gastrointestinal ones, has been observed in other parts of the world.¹⁶

The present study and the one from Mexico City coincide in demonstrating a high frequency of bacterial resistance to antimicrobials that are used very often in Mexico for different infections, such as AMP and T-S, as well as those that are freely used in cases of acute diarrhea, such as NEO and FUR. Resistance to CIP, an antibiotic that has been in use for "only" a little over 30 years, is growing. CHL is an old antibiotic that was widely used for years, but due to its bone marrow toxicity, has been prescribed almost exclusively in cases of typhoid fever for the last few decades. In our study, the frequency of bacteria susceptible to CHL went beyond 75%. FOS is a broad-spectrum antibiotic that is mainly indicated for urinary infections.¹⁷ In contrast, almost all the bacterial strains were susceptible to RIF. The low frequency of bacterial resistance to RIF has also been documented in bacteria associated with cases of traveller's diarrhea coming from Latin America and Asia.^{10-12,18}

There are several reasons that support or explain the low resistance of enteropathogenic bacteria to RIF: *a*) the bacteria that develop resistance to RIF spontaneously disappear from the feces within a few weeks;¹⁹ *b*) a study reported that the MIC₉₀ susceptibility measure of intestinal pathogenic bacteria to RIF did not change with respect to bacteria isolated 10 years earlier;¹¹ *c*) experiments show that resistance to RIF is not easily induced;²⁰ *d*) when resistance appears, it is due to chromosome changes, rather than mediated by plasmids, and therefore it is not easily transmitted to other bacteria;⁷ *e*) when resistant plasmids are induced through sub-inhibitory concentrations, RIF "cures" the plasmids and inhibits the transmission of resistant plasmids, reducing bacterial viability and their virulence, even when they have developed resistance;²¹ and *f*) it has been available in Mexico for fewer than 20 years, but it has been used in European countries for approximately 40 years, with no reports of important resistance.

RIF has been successfully used in acute gastroenteritis in children and adults, including the elderly,^{22,23} in traveller's diarrhea,^{24,25} and associated with other antimicrobials in recurrent diarrhea associated with *Clostridium difficile*.²⁶ It is interesting that in a study on children with acute diarrhea in which RIF significantly shortened diarrhea duration, etiology was not demonstrated in the stool analyses in half of the cases.²² Similarly, in 2 studies on patients with traveller's diarrhea, etiology was not identified in approximately one third of the cases. The patients with "pathogen-negative" diarrhea were analyzed separately and it was shown that

Table 4 Rifaximin actions, in addition to the bactericide effect.

↑ Lactobacilli population
↓ Bacterial adhesion to epithelial cells, ↓ internalization
↓ Bacterial translocation
Activation of pregnane X receptor (↓ of NFκB)
↓ Intestinal expression of proinflammatory cytokines
↓ Endotoxemia in cirrhotic patients
↓ Urease production by enterobacteria and ↓ exotoxins and virulence factors at sub-inhibitory concentrations

rifaximin also shortened diarrhea duration by half.²⁷ Even though this may be due to imperfect diagnostic methods, it could also be that other RIF actions, listed in Table 4, are involved.²⁸⁻³²

When treatment is empiric, bacterial resistance to antibiotics hampers the choice of a useful antibiotic and, in turn, an adequate therapeutic response. According to the data of the present study, if the physician considers indicating empiric treatment with a non-absorbable antibiotic, RIF would be better indicated than NEO. If a gastrointestinal infection with an invasive bacterium (with high fever or bloody diarrhea) is suspected, CIP would be better indicated than FUR. AMP or T-S would not be good choices in any of the cases. Moreover, T-S is the antimicrobial with the greatest frequency of adverse effects.³³

We did not separate the data on bacterial frequency according to age groups or on the bacterial resistance in the samples into adults and children, because only a small number of samples were from children under 10 years of age. Nevertheless, together with data from our previous study, this aspect will be the subject of a sub-analysis in the pediatric population.

In true epidemiologic spirit for the prevention of bacterial resistance, the Mexican guidelines on the diagnosis and treatment of acute diarrhea in pediatric clinical practice suggest not using antimicrobials initially, unless there are clinical signs suggestive of sepsis, there is a bacterial pathogen reported in a stool culture, or the diarrhea occurs in a day-care setting and spread must be prevented. These guidelines take the high frequency of viral diarrhea into account in infants and preschoolers, as well as the fact that in the case of bacterial etiology, the diarrhea resolves in 7 to 14 days, even without antimicrobials.³⁴ In adults, antimicrobials are recommended if the diarrhea persists after 24 to 48 h, if it is severe, or if the pathogenic agent has been identified.³⁵ Other measures can contribute to preventing bacterial resistance to antibiotics, such as strengthening medical education in relation to antimicrobial therapy, avoiding the unrestricted sale of antibiotics, suppressing the indiscriminate use of antibiotics in livestock, and periodically carrying out studies on antimicrobial susceptibility. Epidemiologic surveillance is essential.^{36,37}

Treatment with antimicrobials can be a valuable instrument in the control of gastrointestinal infections. It reduces the duration and intensity of the illness, prevents complications that can be severe, and it can reduce disease transmission. The periodic determination of local, national, and international patterns of antimicrobial susceptibility can contribute to a more rational use of antimicrobial

therapy. Epidemiology can differ from one region to another, especially in a country as large as Mexico. For example, the frequency of *Shigella* was greater in the Southeast of the country than in Mexico City. Evaluating other regions far from the center of Mexico could provide interesting data.

In conclusion, the data contained in the present study was similar to that found in our previous study on patients with acute gastroenteritis in Mexico City: more than 98% of the enteropathogenic bacterial strains were susceptible to RIF and there was a high frequency of resistance to the most commonly used antimicrobials, such as AMP, T-S, NEO, and FUR.

Study limitations. This was not an epidemiologic study on the cause of acute gastroenteritis, and so the frequency of bacterial diarrhea could not be determined in relation to the total number of causes of acute diarrhea. Even though the study was not designed to investigate the prevalence of the different bacteria causing acute gastroenteritis, the bacteria included in the study were dependent on the frequency with which the local laboratories detected them, thus reflecting local prevalence to a certain degree.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Financial disclosure

The study was financed by Alfa Wassermann S.A. de C.V.

Conflict of interest

Alberto C. Frati is currently the medical Director of Alfa Wassermann S.A. de C.V., the distributor of rifaximin in Mexico. He participated in the planning of the project and manuscript revision, but did not intervene in any of the study phases, in the enumeration of results, or in the statistical analysis. The rest of the authors declare that they have no conflict of interest.

References

1. Farthing M, Salam MA, Lindberg G, et al., WGO Global Guidelines. Acute diarrhea in adults and children: A global perspective. *J Clin Gastroenterol.* 2013;47:12–20.
2. Cabrera- Gaytán DA, Maldonado-Burgos MA, Rojas-Mendoza T, et al. Enfermedad diarreica aguda en niños menores de cinco años de edad: aportación de los núcleos trazadores de vigilancia epidemiológica. 2012-2013. *Arch Invest Mat Infant.* 2013;5:118–25.
3. Ferreira GE, Munguía RN, Díaz OI, et al. Diarreas agudas y prácticas de alimentación en niños menores de cinco años en México. *Salud Pub Mex.* 2013;55 Supl. 2:314–22.
4. Secretaría de Salud. Enfermedades diarreicas agudas. Prevención, control y tratamiento. México: Secretaría de Salud; 2010.
5. Hernández Cortez C, Aguilera Arreola MG, Castro Escarpulli G. Situación de las enfermedades gastrointestinales en México. *Enf Inf Microbiol.* 2011;31:137–51.
6. Novoa-Faría O, Frati-Munari AC, Peredo MA, et al. Susceptibilidad de las bacterias aisladas de infecciones gastrointestinales agudas a la rifaximina y otros agentes antimicrobianos en México. *Rev Gastroenterol Mex.* 2016;81:3–10.
7. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. *Digestion.* 2006;73 Suppl 1:13–27.
8. Koneman EW, Allen SD, Janda WM, et al. *Diagnostic microbiology.* 5th ed. Philadelphia: Lippincott; 2000. p. 131–6.
9. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 22 information supplement. M-100-522, 2013. 32(3).
10. Gomi H, Jiang Z, Aldachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. *Antimicrob Agents Chemother.* 2001;45:212–6.
11. Ouyang-Latimer J, Jafri S, Van Tassel A, et al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international traveler's to Mexico, Guatemala, and India from 2006 to 2008. *Antimicrob Agents Chemother.* 2011;55:874–8.
12. Hopkins KL, Mushtak S, Richardson JF, et al. In vitro activity of rifaximin against clinical isolates of *Escherichia coli* and other enteropathogenic bacteria isolated from travelers returning to the UK. *Int J Antimicrob Agents.* 2014;43:431–7.
13. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. *Antimicrob Agents Chemother.* 2000;44:2205–6.
14. Vrints M, Mairiaux E, van Meervenne E, et al. Surveillance of antibiotic susceptibility patterns among *Shigella sonnei* strains isolated in Belgium during the 18-year period 1990 to 2007. *J Clin Microbiol.* 2009;47:1379–85.
15. Cantele A, Lääveri T, Mero S, et al. Antimicrobial increase travelers' risk of colonization by extended-spectrum betalactamase-producing *Enterobacteriaceae*. *Clin Infect Dis.* 2015;60:837–46.
16. Sack RB, Rahman M, Yunus M, et al. Antimicrobial resistance in organisms causing diarrheal disease. *Clin Infect Dis.* 1997;24 Suppl 1:S102–5.
17. Garau M, Latorre A, Alamo-Sanz M. Fosfomicina. Un antibiótico infravalorado en infecciones urinarias por *E. coli*. *Enf Inf Microbiol Clin.* 2001;19:462–6.
18. Jiang ZD, DuPont HL. Rifaximin: In vitro and in vivo antibacterial activity-A review. *Chemotherapy.* 2005;51 Suppl 1:67–72.
19. De Leo, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. *Drugs Exptl Clin Res.* 1986;12:979–81.
20. Dupont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. *Clin Microbiol Infect.* 2004;10:1009–11.
21. Debbia EA, Maioli E, Roveta S, et al. Effect of rifaximin on bacterial virulence mechanisms at supr and sub-inhibitory concentration. *J Chemother.* 2008;29:61–9.
22. Macías Parra M, González Saldaña N, Ramírez Sandoval P, et al. Eficacia y seguridad de rifaximina en el tratamiento del episodio diarreico agudo en niños de seis meses a cinco años. *Rev Enf Inf Pediat.* 2002;16:23–8.
23. Della Marchina M, Renzi G, Palazzini E. Infectious diarrhea in the aged: Controlled clinical trial of rifaximin. *Chemother.* 1988;7:336–40.
24. Taylor D, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of traveler diarrhea. *Am J Trop Med Hyg.* 2006;74:1060–6.

25. DuPont HL, Jiang ZD, Belkin-Gerson J, et al. Treatment of travelers' diarrhea: A randomized trial comparing rifaximin, rifaximin plus loperamide and loperamide alone. *Clin Gastroenterol Hepatol.* 2007;5:451–6.
26. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent *Clostridium difficile*-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. *Clin Infect Dis.* 2007;44:846–8.
27. DuPont HL, Haake R, Taylor DN. Rifaximin treatment of pathogen-negative travelers' diarrhea. *J Travel Med.* 2007;14:16–9.
28. Xue D, Gao J, Gilliland M 3rd, et al. Rifaximin alters intestinal bacteria and prevent stress-induced gut inflammation and visceral hyperalgesia in rats. *Gastroenterology.* 2014;146:484–96.
29. Brown EL, Xue Q, Jiang ZD, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. *Antimicrob Agents Chemother.* 2010;54:388–96.
30. Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocyte reactivity and protects against inflammation in a rodent model of colitis. *Digestion.* 2002;66:246–56.
31. Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation. *J Pharmacol Exp Ther.* 2010;335:32–41.
32. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the microbiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. *PLoS One.* 2013;8:e60042.
33. Shehab N, Patel PR, Srinivasan A, et al. Emergency department visits for antibiotic associated adverse events. *Clin Infect Dis.* 2008;47:735–43.
34. Guía de práctica clínica. Prevención, diagnóstico y tratamiento de la diarrea aguda en niños de dos meses a cinco años en el primero y segundo nivel de atención. Catálogo maestro de guías de práctica clínica. SSA-156-08 [accessed 23 Oct 2015]. Available from: www.cenetec.salud.gob.mx.
35. Guía de práctica clínica. Atención, diagnóstico y tratamiento de la diarrea aguda en adultos en el primer nivel de atención. Catálogo maestro de práctica clínica SSA 106-08 [accessed 28 Oct 2015]. Available from: www.cenetec.salud.gob.mx.
36. Remes Troche JM. Reflexiones sobre la resistencia a antibióticos y que hacer al respecto. *Rev Gastroenterol Mex.* 2016;81:1–2.
37. Dar OA, Hasan R, Schlundt J, et al. Exploring the evidence base for national and regional policy intervention to combat resistance. *Lancet.* 2016;387:285–95.